Stocks and Investing Stocks and Investing
Wed, July 10, 2019
Tue, July 9, 2019

Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $220 on, Jul 9th, 2019


Published on 2024-10-26 14:32:02 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $165 to $220 on, Jul 9th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $220 on, Monday, July 1st, 2019
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $190 on, Thursday, May 16th, 2019
Contributing Sources